[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,111,727
  • Shares Outstanding, K 37,275
  • Annual Sales, $ 272,300 K
  • Annual Income, $ -5,140 K
  • EBIT $ 31 M
  • EBITDA $ 54 M
  • 60-Month Beta 0.34
  • Price/Sales 3.97
  • Price/Cash Flow 33.59
  • Price/Book 38.17

Options Overview Details

View History
  • Implied Volatility 58.66% (-4.64%)
  • Historical Volatility 86.10%
  • IV Percentile 13%
  • IV Rank 14.95%
  • IV High 110.75% on 08/07/25
  • IV Low 49.50% on 08/29/25
  • Expected Move (DTE 35) 3.57 (11.57%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 2,469
  • Volume Avg (30-Day) 1,292
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 45,954
  • Open Int (30-Day) 41,793
  • Expected Range 27.29 to 34.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.02
  • Number of Estimates 2
  • High Estimate $0.10
  • Low Estimate $-0.06
  • Prior Year $0.24
  • Growth Rate Est. (year over year) -91.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.54 +8.13%
on 05/13/26
42.13 -26.75%
on 04/17/26
-7.04 (-18.58%)
since 04/14/26
3-Month
28.54 +8.13%
on 05/13/26
54.49 -43.37%
on 02/26/26
-16.83 (-35.29%)
since 02/13/26
52-Week
24.62 +25.35%
on 05/15/25
54.85 -43.74%
on 01/07/26
+5.74 (+22.83%)
since 05/14/25

Most Recent Stories

More News
Harrow Q1 Earnings Call Highlights

Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized...

HROW : 30.86 (+3.47%)
Harrow: Q1 Earnings Snapshot

Harrow: Q1 Earnings Snapshot

HROW : 30.86 (+3.47%)
Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights:  VEVYE ® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE...

HROW : 30.86 (+3.47%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 30.86 (+3.47%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 30.86 (+3.47%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 30.86 (+3.47%)
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 30.86 (+3.47%)
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE ® 1% (apraclonidine...

HROW : 30.86 (+3.47%)
LogiCare3PL Selected as Distribution Partner by Harrow

OLIVE BRANCH, Miss. , April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic...

HROW : 30.86 (+3.47%)
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private...

HROW : 30.86 (+3.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 34.55
2nd Resistance Point 33.02
1st Resistance Point 31.94
Last Price 30.86
1st Support Level 29.33
2nd Support Level 27.80
3rd Support Level 26.72

See More

52-Week High 54.85
Fibonacci 61.8% 43.30
Fibonacci 50% 39.74
Fibonacci 38.2% 36.17
Last Price 30.86
52-Week Low 24.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.